CU20180035A7 - Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas - Google Patents

Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas

Info

Publication number
CU20180035A7
CU20180035A7 CUP2018000035A CU20180035A CU20180035A7 CU 20180035 A7 CU20180035 A7 CU 20180035A7 CU P2018000035 A CUP2018000035 A CU P2018000035A CU 20180035 A CU20180035 A CU 20180035A CU 20180035 A7 CU20180035 A7 CU 20180035A7
Authority
CU
Cuba
Prior art keywords
treatment
diseases
prevention
attended
influenza
Prior art date
Application number
CUP2018000035A
Other languages
English (en)
Other versions
CU24580B1 (es
Inventor
Andrei Yurievich Egorov
Boris Ferko
Artem Alexandrovich Krokhin
Yulia Romanovna Romanova
Original Assignee
«Pharmenterprises Biotech›› Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2016111907A external-priority patent/RU2660562C2/ru
Application filed by «Pharmenterprises Biotech›› Llc filed Critical «Pharmenterprises Biotech›› Llc
Publication of CU20180035A7 publication Critical patent/CU20180035A7/es
Publication of CU24580B1 publication Critical patent/CU24580B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

<p>La presente invención se refiere al campo de Ia medicina y Ia virología; se proporcionan un virus de influenza A atenuado, un vector de virus de influenza basado en el mismo, y una composición farmacéutica que comprende el mismo, que se puede usar para Ia prevención y/o el tratamiento de una enfermedad infecciosa; además, Ia presente invención se refiere a un virus de influenza A atenuado, un vector de virus de Ia influenza basado en el mismo, y una composición farmacéutica que comprende el mismo, que puede usarse para el tratamiento de enfermedades oncológicas.</p>
CU2018000035A 2015-11-06 2016-11-03 Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas CU24580B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2015147703A RU2628690C2 (ru) 2015-11-06 2015-11-06 Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
RU2016111907A RU2660562C2 (ru) 2016-03-30 2016-03-30 Аттенуированный гриппозный вектор и мукозальная универсальная гриппозная вакцина на его основе
PCT/RU2016/050066 WO2017078577A2 (ru) 2015-11-06 2016-11-03 Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний

Publications (2)

Publication Number Publication Date
CU20180035A7 true CU20180035A7 (es) 2018-07-05
CU24580B1 CU24580B1 (es) 2022-02-04

Family

ID=58662984

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2018000035A CU24580B1 (es) 2015-11-06 2016-11-03 Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas

Country Status (15)

Country Link
US (1) US10392604B2 (es)
EP (1) EP3382010A4 (es)
JP (1) JP6692835B2 (es)
KR (1) KR102604877B1 (es)
CN (1) CN108026515B (es)
AU (1) AU2016350939B9 (es)
CA (1) CA2991023C (es)
CU (1) CU24580B1 (es)
IL (1) IL255259B (es)
MA (1) MA43314A (es)
MX (1) MX380393B (es)
RU (1) RU2628690C2 (es)
SG (1) SG11201709122VA (es)
UA (1) UA125333C2 (es)
WO (1) WO2017078577A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3632433B1 (en) * 2017-05-26 2025-12-24 Vladimir Evgenievich Nebolsin Novel glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases
US12178869B2 (en) * 2017-12-22 2024-12-31 Codagenix Inc. Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer
WO2019172982A1 (en) 2018-03-08 2019-09-12 Codagenix Inc. Attenuated flaviviruses
CN111315407B (zh) 2018-09-11 2023-05-02 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
KR102370100B1 (ko) * 2019-02-15 2022-03-07 아이디바이오 주식회사 이종 인플루엔자 a 바이러스에 대한 면역/치료반응을 형성하는 신규한 재조합 인플루엔자 바이러스 및 이를 포함하는 유전자 전달체 및 치료백신
RU2726106C1 (ru) * 2019-07-18 2020-07-09 федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ гриппа им. А.А. Смородинцева" Минздрава России) Рекомбинантный штамм вируса гриппа A/PR8-NS124-TB10.4-2A-HspX и способ специфической профилактики туберкулеза легких с использованием вакцины мукозального применения на его основе
AU2021342299A1 (en) * 2020-09-11 2023-04-13 The United States Of America, As Represented By The Secretary Of Agriculture Compositions and methods of use thereof for prevention and treatment of influenza infections
US12440553B2 (en) * 2020-11-11 2025-10-14 California Institute Of Technology Multivalent carriers and related vaccine compositions
CN113430178B (zh) * 2021-06-21 2022-10-11 武汉大学 一种表达ii型单纯疱疹病毒蛋白的重组流感病毒株及其制备方法与应用
WO2025041889A1 (ko) * 2023-08-24 2025-02-27 성신여자대학교 연구산학협력단 외래 항원을 발현하는 재조합 인플루엔자 바이러스 벡터 및 이를 포함하는 백신 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4837827B2 (ja) * 1998-06-12 2011-12-14 マウント シナイ スクール オブ メディシン 新規なウイルス増殖方法およびそのためのインターフェロン欠損培養基
DE69937999T2 (de) * 1998-06-12 2009-01-29 Avir Green Hills Biotechnology Research Development Trade Ag Interferon induzierende genetisch veränderte attenuierte viren
WO2001064860A2 (en) * 2000-03-02 2001-09-07 Polymun Scientific Immunbiologische Forschung Gmbh Recombinant influenza a viruses
US7037707B2 (en) * 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
US7709190B2 (en) * 2005-12-02 2010-05-04 Board Of Regents, The University Of Texas System Influenza A virus vaccines and inhibitors
EP2048237A1 (en) 2007-10-05 2009-04-15 Avir Green Hills Biotechnology Research Development Trade Ag Replication deficient Influenza virus for the expression of heterologous sequences
EP2072058A1 (en) * 2007-12-21 2009-06-24 Avir Green Hills Biotechnology Research Development Trade Ag Modified influenza virus
US9217157B2 (en) * 2009-07-27 2015-12-22 Icahn School Of Medicine At Mount Sinai Recombinant influenza viruses and uses thereof
US8828406B2 (en) * 2009-07-30 2014-09-09 Icahn School Of Medicine At Mount Sinai Influenza viruses and uses thereof
WO2011130652A2 (en) * 2010-04-15 2011-10-20 George Baer Compositions and methods for vaccinating humans and animals against enveloped viruses
JP2013531496A (ja) * 2010-06-06 2013-08-08 モウント シナイ スクール オフ メディシネ 組換えｒｎａウイルス及びその使用
EP2646459B1 (en) * 2010-12-02 2020-01-08 Bionor Immuno AS Peptide scaffold design
EP2708552A1 (en) * 2012-09-12 2014-03-19 Medizinische Universität Wien Influenza virus

Also Published As

Publication number Publication date
US10392604B2 (en) 2019-08-27
MA43314A (fr) 2018-10-03
IL255259B (en) 2020-03-31
JP6692835B2 (ja) 2020-05-13
HK1251616A1 (zh) 2019-02-01
KR102604877B1 (ko) 2023-11-23
MX380393B (es) 2025-03-12
US20180245052A1 (en) 2018-08-30
UA125333C2 (uk) 2022-02-23
WO2017078577A2 (ru) 2017-05-11
AU2016350939A2 (en) 2018-02-08
RU2628690C2 (ru) 2017-08-21
CA2991023A1 (en) 2017-05-11
RU2015147703A (ru) 2017-05-16
WO2017078577A3 (ru) 2017-06-29
CA2991023C (en) 2025-05-13
AU2016350939A1 (en) 2017-11-23
MX2017015462A (es) 2018-03-07
SG11201709122VA (en) 2017-12-28
BR112017025435A2 (pt) 2018-09-11
IL255259A (en) 2018-04-30
KR20180067464A (ko) 2018-06-20
BR112017025435A8 (pt) 2019-08-20
AU2016350939B9 (en) 2021-07-22
CN108026515B (zh) 2022-03-11
AU2016350939B2 (en) 2021-07-08
JP2018531578A (ja) 2018-11-01
EP3382010A4 (en) 2019-03-27
EP3382010A2 (en) 2018-10-03
CU24580B1 (es) 2022-02-04
CN108026515A (zh) 2018-05-11

Similar Documents

Publication Publication Date Title
CU20180035A7 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
CL2019001433A1 (es) Moduladores de la proteína core de la hepatitis b. (divisional solicitud 201800684)
CL2017001798A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas.
UY37252A (es) Compuestos para el tratamiento de infección por virus de la hepatitis b
MX2019003525A (es) Moduladores alostericos de proteina nucleo de hepatitis b.
MX2020012132A (es) Compuestos de azapiridona y usos de los mismos.
GT201500020A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
EA201790266A1 (ru) Индолы для применения при инфекции, вызванной вирусом гриппа
EA201790700A1 (ru) Моно- или дизамещенные индолы в качестве ингибиторов репликации вирусов денге
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
MX2017011655A (es) Compuestos de aza-piridona y usos de estos.
MX383330B (es) Particula tipo virus de flavivirus.
CO2018007810A2 (es) Formulación líquida estable de gonadotropina
CO7131387A2 (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
CL2016000300A1 (es) Métodos terapéuticos
CL2017000329A1 (es) Mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
UY35418A (es) Vacuna que proporciona protección frente a diferentes Picornavirus humanos.
CR20160353A (es) Inhibidor de proteína de transferencia del éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden el inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
EA201790776A1 (ru) Комбинированные композиции длительного действия и способы лечения гепатита с
AR095118A1 (es) Un procedimiento de inactivación viral en composición que comprende factor vii
CL2018001201A1 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas.
AR111683A1 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
EA201691835A1 (ru) Аллостерические модуляторы капсидного белка гепатита в
TH1601005264A (es)